Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Marrow transplantation as salvage therapy in non-Hodgkin's lymphoma seems to be superior to chemotherapy administered in conventional doses, although trials are ongoing. Transplantation results are better when refractory and relapsed patients respond to conventional salvage therapy (sensitive relapse) and residual disease is reduced to a minimum. The authors summarize clinical findings to date, including the latest work with interferon and monoclonal antibodies.

Original languageEnglish (US)
Pages (from-to)11-21
Number of pages11
JournalOncology (Williston Park, N.Y.)
Volume1
Issue number9
StatePublished - Nov 1987

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Salvage therapy for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.'. Together they form a unique fingerprint.

  • Cite this